Generic Drug Prescribing: Where the Legal Requirement Actually Stands in 2026

Few NMC-related controversies have generated as much conflicting, half-updated coverage as the generic prescribing mandate. Depending on which article a doctor reads, they might come away believing this is settled, currently enforced law with licence-suspension penalties — or a proposal that collapsed entirely under industry pressure. Neither picture is fully accurate. This article untangles what’s actually in force, what’s shelved, and what a recent Supreme Court observation has added to the mix.

The Provision That Predates the 2023 Controversy

It’s a common misconception that the generic-prescribing requirement originated entirely with the widely reported August 2023 NMC notification. In fact, a version of this obligation already exists within the operative Indian Medical Council (Professional Conduct, Etiquette and Ethics) Regulations, 2002 (as amended) — Clause 1.5 states that every physician should prescribe drugs with generic names, legibly and preferably in capital letters, and should ensure rational prescription and use of drugs. This clause has been part of the standing, currently applicable ethics code for years, independent of the 2023 episode.

What Changed in August 2023

On August 2, 2023, the NMC’s Ethics and Medical Registration Board notified the National Medical Commission Registered Medical Practitioner (Professional Conduct) Regulations, 2023, which restated and significantly sharpened this obligation — explicitly warning that non-compliance could draw penalties including temporary suspension of a doctor’s licence to practise, and adding related provisions such as a proposed ban on doctors participating in pharmaceutical-company-sponsored third-party educational activities. This version prompted immediate, forceful opposition from the Indian Medical Association and the Indian Pharmaceutical Alliance, who argued the government could not fairly hold doctors solely responsible for medicine quality while continuing to license branded, non-generic drugs without a parallel commitment to certifying the quality of every generic product on the market.

The Abeyance: Why This Matters Here Too

As covered in more depth elsewhere in this series, the entire 2023 Regulations — including this sharpened generic-prescribing clause and its explicit suspension penalty — were placed in abeyance by the NMC on August 23-24, 2023, roughly three weeks after notification, following the IMA and IPA’s direct appeal to the Union Health Minister. The 2002 Code was reinstated with immediate effect, and the NMC’s own website continues to list the 2023 Regulations as held in abeyance pending further gazette notification, as of this writing.

So What’s Actually Binding Right Now?

This is the part most coverage gets muddled: the abeyance did not eliminate the generic-prescribing obligation entirely — it eliminated the 2023 version’s sharper penalty language and its accompanying pharma-sponsorship restrictions. The underlying Clause 1.5 obligation from the 2002 Code — prescribe drugs by generic name, legibly, preferably in capital letters, and prescribe rationally — remains part of the currently operative ethics framework, just without the 2023 notification’s more explicit suspension threat attached to it.

This is directly confirmed by a more recent development: in December 2025, the NMC directed all medical colleges to establish a sub-committee under their Drugs and Therapeutics Committee to monitor prescription practices, explicitly stating that “according to current regulations,” physicians are required to prescribe drugs using generic names, written legibly and preferably in capital letters. This December 2025 directive draws on the standing 2002 Code obligation — not a reactivated 2023 Regulation — confirming that the generic-name requirement itself was never actually suspended, even though its 2023 penalty enhancement was.

The Legible Prescriptions Trigger: A Punjab & Haryana High Court Ruling

The December 2025 NMC directive was itself a direct response to a court order — the Punjab and Haryana High Court’s ruling dated August 27, 2025, in Yogesh v. State of Haryana, which held that legible medical prescriptions are essential to the Right to Health guaranteed under Article 21 of the Constitution. This ruling is covered in full in a companion article; the key point for the generic-prescribing question is that it gave the NMC’s existing Clause 1.5 obligation renewed institutional teeth, requiring medical colleges to actively audit and document prescription practices — including generic-name use — rather than treating the obligation as a passive, rarely enforced ethical guideline.

A 2025 Supreme Court Observation Worth Understanding Correctly

Separately, in the course of hearing a public interest litigation concerning pharmaceutical marketing practices — brought by the Federation of Medical & Sales Representatives Associations of India, focused on the influence of pharma promotional spending on prescribing behaviour — the Supreme Court made an oral observation suggesting doctors nationwide should be required to prescribe only generic medicines rather than branded ones. It is important to be precise about what this was: an observation made during a hearing on a related but distinct issue (drug marketing regulation), not a standalone, binding judicial order specifically mandating generic-only prescribing as new, enforceable law. Doctors should treat this as a significant signal of judicial attention to the issue, not as a change to the operative legal requirement itself.

The Core Objection From Medical Bodies, Explained

The IMA’s central argument throughout this controversy has been consistency: if the government is confident enough in generic drug quality to require doctors to prescribe exclusively by generic name, it should apply the same confidence to phasing out branded drug licensing altogether, or invest more visibly in verifying generic manufacturing quality — rather than placing the clinical and reputational risk of any quality variation entirely on the prescribing doctor. This remains the crux of ongoing debate and is likely to resurface each time the underlying regulation is strengthened or reactivated.

What This Means for a Practising Doctor Today

1. Treat generic-name prescribing and legible handwriting as a standing obligation under the operative 2002 Code (Clause 1.5) — not something you can disregard simply because the 2023 Regulations are in abeyance.
2. If your prescriptions are not consistently generic-name and legible, address this now, given the renewed institutional monitoring following the Punjab & Haryana High Court ruling and the NMC’s December 2025 directive.
3. Where a branded formulation is genuinely clinically necessary (a specific fixed-dose combination, a narrow-therapeutic-index drug where bioequivalence variation matters), document the clinical reasoning contemporaneously — several state-level directives have specifically suggested maintaining a dated record of reasons for prescribing a branded drug in exceptional circumstances.
4. Watch for any future gazette notification reactivating the 2023 Regulations’ enhanced penalty structure, since the underlying obligation remaining in force does not mean the stricter version couldn’t return.
5. Recognise that this remains a live, actively evolving legal and policy area, not a settled question — the Supreme Court’s continued engagement with related pharmaceutical marketing litigation makes further developments likely.

Frequently Asked Questions

Is it currently mandatory for Indian doctors to prescribe only generic medicines?

The obligation to prescribe using generic names, written legibly, exists under the operative 2002 Code (Clause 1.5) and has recently been reinforced through NMC directives to medical colleges — but the 2023 Regulations’ more explicit, standalone licence-suspension penalty for non-compliance remains in abeyance.

Can a doctor still prescribe a branded medicine at all?

The standing obligation is to prescribe by generic name as the default; some state-level guidance has suggested doctors document specific clinical reasons when a branded medicine is genuinely necessary, though a comprehensive, uniformly enforced national exception process has not been finalised.

Did the Supreme Court order doctors to only prescribe generics?

The Supreme Court made an oral observation on this point during a hearing on a related pharmaceutical marketing PIL — this is a significant signal but is distinct from a standalone binding order specifically mandating generic-only prescribing as new law.

Why did the NMC direct medical colleges to monitor prescriptions in December 2025?

This followed a Punjab and Haryana High Court ruling in August 2025 holding that legible prescriptions are essential to the constitutional Right to Health, prompting the NMC to require colleges to actively audit and document compliance with the existing generic-name and legibility obligation.

What happens if a doctor’s prescriptions are found illegible or consistently branded without documented justification?

Under the currently operative framework, this is treated as a compliance issue under the 2002 Code, monitored increasingly actively at the institutional level following the 2025 court ruling; the specific disciplinary consequence depends on the relevant State Medical Council’s enforcement approach, since the 2023 Regulations’ explicit penalty schedule is not currently in force.

Researched Sources

1. Careers360 — NMC Directs Medical Colleges to Ensure Legible Prescriptions, Use of Generic Names
2. Business Standard — Doctors Must Prescribe Only Generic Drugs, Not Branded Medicines: SC
3. The Tribune — NMC Puts Generic Drugs Order on Hold
4. Journal of Medical Evidence — National Medical Commission’s Generic Drug Policy: A Boon or a Bane

Disclaimer

This article is for general informational and educational purposes and reflects the regulatory position on generic prescribing as understood at the time of writing; this is an actively evolving and contested area of medical regulation. It is not legal advice; doctors should consult a qualified healthcare lawyer or their State Medical Council to confirm current, specific obligations.